The impact of technology diffusion on treatment for prostate cancer

Medical Care

Volumn 51, Issue 12, 2013, Pages 1076-1084

  Schroeck, Florian R ^a   Kaufman, Samuel R ^a   Jacobs, Bruce L ^a   Zhang, Yun ^a   Weizer, Alon Z ^a   Montgomery, Jeffrey S ^a   Gilbert, Scott M ^b   Strope, Seth A ^c   Hollenbeck, Brent K ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

intensity modulated radiotherapy; prostate cancer treatment; robotic prostatectomy; technology

Indexed keywords

AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; COHORT ANALYSIS; DIFFUSION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LOCAL THERAPY; MAJOR CLINICAL STUDY; MALE; MARKET; PATIENT REFERRAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; ROBOTICS; TECHNOLOGY;

AGE FACTORS; AGED; AGED, 80 AND OVER; DIFFUSION OF INNOVATION; HEALTH SERVICES RESEARCH; HUMANS; MALE; MEDICARE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; ROBOTICS; SEER PROGRAM; UNITED STATES; WATCHFUL WAITING;

EID: 84888114000     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000019     Document Type: Article

References (40)

1. Newhouse JP. Medical care costs: How much welfare loss? J Econ Perspect. 1992;6:3-21
2. Maxwell S, Zuckerman S, Berenson RA. Use of physicians' services under Medicare's resource-based payments. N Engl J Med. 2007;356: 1853-1861
3. Medicare Payment Advisory Commission. March 2012 Report to the Congress: Medicare Payment Policy. 2012. Available at: Http://medpac.gov/ documents/Mar12-EntireReport.pdf. Accessed March 12, 2013
4. Cutler DM, McClellan M. Is technological change in medicine worth it? Health Affairs. 2001;20:11-29
5. Legorreta AP, Silber JH, Costantino GN, et al. Increased cholecystectomy rate after the introduction of laparoscopic cholecystectomy. JAMA. 1993;270:1429-1432
6. Escarce JJ, Chen W, Schwartz JS. Falling cholecystectomy thresholds since the introduction of laparoscopic cholecystectomy. JAMA. 1995; 273:1581-1585
7. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103:117-128
8. Stamatiou K, Alevizos A, Mariolis A, et al. Do clinically insignificant tumors of the prostate exist? Urol Int. 2008;81:379-382
9. Klotz L, Zhang L, Lam A, et al. Clinical results of long-Term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126-131
10. Staffurth J. A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol). 2010;22:643-657
11. Ficarra V, Cavalleri S, Novara G, et al. Evidence from robot-Assisted laparoscopic radical prostatectomy: A systematic review. Eur Urol. 2007;51:45-56
12. Jacobs BL, Zhang Y, Skolarus TA, et al. Comparative effectiveness of external-beam radiation approaches for prostate cancer. Eur Urol. July 6 2013. Epub ahead of print. Available at: Http://dx.doi.org/10.1016/ j.eururo.2012.06.055. Accessed September 25, 2012
13. Scales CD Jr, Jones PJ, Eisenstein EL, et al. Local cost structures and the economics of robot assisted radical prostatectomy. J Urol. 2005;174: 2323-2329
14. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011;29:1517-1524
15. Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53:1258-1267
16. Schroeck FR, Kaufman SR, Jacobs BL, et al. Technology diffusion and diagnostic testing for prostate cancer. J Urol. 2013;190:1715-1720
17. The Dartmouth Institute for Health Policy & Clinical Practice. Glossary-Dartmouth atlas of health care. 2012. Available at: Http:// www.dartmouthatlas.org/tools/glossary.aspx. Accessed April 7, 2012
18. Pollack CE, Weissman G, Bekelman J, et al. Physician social networks and variation in prostate cancer treatment in three cities. Health Serv Res. 2012;47:380-403
19. US Census Bureau. ZIP Code Tabulation Areas. Available at: Http:// www.census.gov/geo/ZCTA/zcta.html. Accessed March 27, 2013
20. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974
21. Williams RL. A note on robust variance estimation for clustercorrelated data. Biometrics. 2000;56:645-646
22. Vittinghoff E, Glidden DW, Shiboski SC, et al. Chapter 10: Predictor selection. In: Vittinghoff E, Glidden DW, Shiboski SC, et al, eds. Regression Methods in Biostatistics. 2nd ed. New York: Springer US; 2012:395-429
23. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302: 1202-1209
24. Walter LC, Bertenthal D, Lindquist K, et al. PSA screening among elderly men with limited life expectancies. JAMA. 2006;296:2336-2342
25. So C, Kirby KA, Mehta K, et al. Medical center characteristics associated with PSA screening in elderly veterans with limited life expectancy. J Gen Intern Med. 2012;27:653-660
26. Makarov DV, Yu JB, Desai RA, et al. The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care. 2011; 49:333-339
27. Neuner JM, See WA, Pezzin LE, et al. The association of robotic surgical technology and hospital prostatectomy volumes. Cancer. 2012; 118:371-377
28. Stitzenberg KB, Wong Y, Nielsen ME, et al. Trends in radical prostatectomy: Centralization, robotics, and access to urologic cancer care. Cancer. 2012;118:54-62
29. Jacobs BL, Zhang Y, Skolarus TA, et al. Growth of high-cost intensitymodulated radiotherapy for prostate cancer raises concerns about overuse. Health Affairs. 2012;31:750-759
30. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358:1250-1261
31. Brooks MJ, Sutton R, Sarin S. Comparison of surgical risk score, POSSUM and p-POSSUM in higher-risk surgical patients. Br J Surg. 2005;92:1288-1292
32. Zietman A, Goitein M, Tepper JE. Technology evolution: Is it survival of the fittest? J Clin Oncol. 2010;28:4275-4279
33. Carter HB, Partin AW, Walsh PC, et al. Gleason score 6 adenocarcinoma: Should it be labeled as cancer? J Clin Oncol. 2012;30: 4294-4296
34. Miller DC, Gruber SB, Hollenbeck BK, et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006;98:1134-1141
35. Etzioni R, Mucci LA, Chen S, et al. Increasing use of radical prostatectomy for non-lethal prostate cancer in Sweden. Clin Cancer Res. 2012;18:6742-6747
36. Carreyrou J, Tamman M. A device to kill cancer, lift revenue. Wall Street Journal. 2010. Available at: Http://online.wsj.com/article/SB100014240 52748703904804575631222900534954.html. Accessed January 4, 2013
37. Barbash GI, Glied SA. New technology and health care costs-The case of robot-Assisted surgery. N Engl J Med. 2010;363:701-704
38. Jacobs BL, Zhang Y, Schroeck FR, et al. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA. 2013;309:2587-2595
39. Cooperberg MR, Ramakrishna NR, Duff SB, et al. Primary treatments for clinically localised prostate cancer: A comprehensive lifetime costutility analysis. BJU Int. 2013;111:437-450
40. Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141-2149